Nitazoxanide Bilayer Formulation for Hepatitis C
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of nitazoxanide and tizoxanide for treating chronic hepatitis C suffer from variable absorption, short half-life, and significant side effects, limiting their efficacy and patient compliance due to frequent dosing and intestinal tract-related issues.
Innovation Solution
Development of controlled release solid dosage formulations combining a controlled release portion and an immediate release portion of nitazoxanide or its analogues, utilizing a low-viscosity polymer to extend absorption and reduce side effects, administered as tablets or capsules for improved bioavailability and reduced frequency of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional immediate release formulations are used, then rapid absorption occurs, but the half-life is short requiring frequent dosing
Solution Approach 1:
The formulation is segmented into two distinct portions: an immediate release portion containing nitazoxanide and tizoxanide for rapid absorption, and a controlled release portion containing nitazoxanide for sustained release. This segmentation allows the drug to provide both rapid initial therapeutic effect and prolonged duration of action, eliminating the need for frequent dosing while maintaining effective plasma concentrations.
Solution Approach 2:
The invention changes the release rate parameter of the drug formulation by incorporating a controlled release portion that releases nitazoxanide at a reduced rate compared to immediate release formulations. This parameter change extends the duration of action from approximately 1.5 hours to a much longer period, allowing once-daily or less frequent dosing while maintaining therapeutic efficacy.
2Reliability
If higher doses are administered to improve efficacy, then treatment effectiveness increases, but side effects increase significantly
Solution Approach 1:
The controlled release portion provides continuous, sustained release of nitazoxanide over an extended period, maintaining stable plasma concentrations within the therapeutic window. This continuous action ensures reliable treatment efficacy without the peaks and troughs associated with immediate release formulations, thereby preventing side effects that occur with high peak concentrations while maintaining effective drug levels throughout the dosing interval.
Solution Approach 2:
The controlled release formulation acts as an intermediary mechanism that modulates the delivery of nitazoxanide to the body. By controlling the rate and timing of drug release, it mediates between the need for high doses to achieve efficacy and the need to limit doses to avoid side effects, delivering the optimal amount of drug at optimal times to maximize therapeutic benefit while minimizing adverse effects.
3Reliability
If frequent dosing is required to maintain therapeutic levels, then efficacy is maintained, but patient compliance decreases
Solution Approach 1:
The formulation dynamically adjusts drug release to match the body's needs: the immediate release portion provides a rapid initial dose to quickly achieve therapeutic levels, while the controlled release portion then maintains those levels over an extended period. This dynamic release profile allows for less frequent dosing (improving compliance) while ensuring therapeutic levels are maintained throughout the dosing interval (maintaining efficacy).
Data Source
AI summary
Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.